Go Pro
Joel Beatty

Joel Beatty Analyst Performance

Biotechnology Equity Research Analyst at Robert W. Baird

Joel Beatty is a stock analyst at Robert W. Baird focused in the healthcare sector, covering 37 publicly traded companies. Over the past year, Joel Beatty has issued 26 stock ratings, including buy and hold recommendations. While full access to Joel Beatty's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Joel Beatty's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
100 Last 11 Years
Buy Recommendations
79.12% 72 Buy Ratings
Companies Covered
37 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy79.1%72 ratings
Hold19.8%18 ratings
Sell1.1%1 ratings

Out of 91 total stock ratings issued by Joel Beatty at Robert W. Baird, the majority (79.1%) have been Buy recommendations, followed by 19.8% Hold and 1.1% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
97.3% of companies on NASDAQ
36 companies
NYSE
2.7% of companies on NYSE
1 company

Joel Beatty, an analyst at Robert W. Baird, currently covers 37 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
36 companies
97.3%
Consumer Staples
1 company
2.7%

Joel Beatty of Robert W. Baird specializes in stock coverage within the Healthcare sector, with additional focus on Consumer Staples companies.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
27 companies
73.0%
PHARMACEUTICALS
9 companies
24.3%
PERSONAL CARE PRODUCTS
1 company
2.7%

Joel Beatty's Ratings History at Robert W. Baird

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
8/7/2026Set Price Target$355.45$514.00
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
8/7/2026Set Price Target$25.10$34.00
e.l.f. Beauty stock logo
ELF
e.l.f. Beauty
8/6/2026Set Price Target$93.97$105.00
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
8/4/2026Boost Price Target$251.58$280.00Outperform
Alkermes plc stock logo
ALKS
Alkermes
7/29/2026Boost Price Target$50.50$58.00Outperform
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
6/30/2026Lower Price Target$3.20$5.00Outperform
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
6/18/2026Boost Price Target$17.12$33.00Outperform
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
6/2/2026Lower Price Target$335.16$400.00Outperform
Alkermes plc stock logo
ALKS
Alkermes
5/13/2026Boost Price Target$38.29$48.00Outperform
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
5/5/2026Boost Price Target$224.03$246.00Outperform
e.l.f. Beauty stock logo
ELF
e.l.f. Beauty
4/28/2026Lower Price Target$63.73$90.00Outperform
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
4/7/2026Boost Price Target$19.38$34.00Outperform
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
3/26/2026Boost Price Target$22.47$32.00Outperform
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
3/13/2026Downgrade$2.76$1.00Neutral
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
3/10/2026Boost Price Target$79.23$132.00Outperform
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
3/6/2026Boost Price Target$13.81$20.00Outperform
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
2/20/2026Set Price Target$331.61$433.00Outperform
e.l.f. Beauty stock logo
ELF
e.l.f. Beauty
2/5/2026Set Price Target$84.55$115.00
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
12/30/2025Lower Price Target$22.28$47.00Outperform
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
11/24/2025Lower Price Target$10.67$14.00Outperform
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
11/18/2025Boost Price Target$173.98$209.00Outperform
e.l.f. Beauty stock logo
ELF
e.l.f. Beauty
11/6/2025Lower Price Target$76.28$125.00Outperform
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
10/16/2025Boost Price Target$15.79$19.00Outperform
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
9/30/2025Lower Price Target$3.38$7.00Outperform
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
9/9/2025Boost Price Target$31.80$67.00Outperform
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
8/13/2025Boost Price Target$2.29$6.00Outperform
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
8/8/2025Set Price Target$45.38$70.00
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
7/8/2025Boost Price Target$9.35$9.00Neutral
e.l.f. Beauty stock logo
ELF
e.l.f. Beauty
6/6/2025Boost Price Target$118.65$145.00Outperform
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
5/19/2025Boost Price Target$21.76$31.00Outperform
e.l.f. Beauty stock logo
ELF
e.l.f. Beauty
5/14/2025Boost Price Target$78.35$100.00Outperform
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
5/13/2025Lower Price Target$1.54$4.00Outperform
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
5/13/2025Lower Price Target$20.08$50.00Outperform
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
5/8/2025Lower Price Target$14.26$29.00Outperform
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
5/7/2025Lower Price Target$40.26$66.00Outperform
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
5/7/2025Lower Price Target$102.22$155.00Outperform
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
5/7/2025Lower Price Target$4.74$7.00Neutral
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
5/6/2025Boost Price Target$116.49$162.00Outperform
Alkermes plc stock logo
ALKS
Alkermes
5/2/2025Boost Price Target$30.58$41.00Outperform
Neurogene Inc. stock logo
NGNE
Neurogene
3/25/2025Set Price Target$8.20$38.00
Your 401(k) May Not Be Ready for This (Ad)

The U.S. is sitting on 8,133 tonnes of gold still valued at 1973 prices. One executive order could correct that - and analysts say it would set off the largest wealth transfer most living Americans have ever seen. The last time Washington made a comparable move, one asset climbed 2,300% in under 10 years. Those who positioned early changed their financial lives. The window to act before any order is signed may be narrow.tc pixel

Learn how to position yourself in gold before the order is signed
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
3/25/2025Lower Price Target$2.28$10.00Outperform
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
3/7/2025Lower Price Target$6.61$16.00Outperform
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
3/7/2025Lower Price Target$6.44$16.00Outperform
argenex SE stock logo
ARGX
argenex
3/4/2025Boost Price Target$631.50$680.00Neutral
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
3/3/2025Lower Price Target$38.60$73.00Outperform
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
3/3/2025Boost Price Target$22.89$32.00Outperform
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
3/3/2025Boost Price Target$127.54$160.00Outperform
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
2/27/2025Lower Price Target$6.71$8.00Neutral
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
2/4/2025Initiated Coverage$22.62$28.00Outperform
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2/3/2025Set Price Target$137.75$132.00